PI3K and MEK inhibitor combinations: examining the evidence in selected tumor types. (Q38084846): Difference between revisions

From Wikidata

Jump to navigation Jump to search

Browse history interactively

← Older edit Newer edit →

Revision as of 17:45, 15 May 2021

scientific article published on 27 February 2013

Language	Label	Description	Also known as
English	PI3K and MEK inhibitor combinations: examining the evidence in selected tumor types.	scientific article published on 27 February 2013

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

28 August 2017

PI3K and MEK inhibitor combinations: examining the evidence in selected tumor types. (English)

1 reference

Europe PubMed Central

PubMed publication ID

28 August 2017

author name string

Carolyn D Britten

1

1 reference

Europe PubMed Central

PubMed publication ID

28 August 2017

publication date

27 February 2013

1 reference

Europe PubMed Central

PubMed publication ID

28 August 2017

Cancer Chemotherapy and Pharmacology

1 reference

Europe PubMed Central

PubMed publication ID

28 August 2017

71

1 reference

Europe PubMed Central

PubMed publication ID

28 August 2017

6

1 reference

Europe PubMed Central

PubMed publication ID

28 August 2017

1395-1409

1 reference

Europe PubMed Central

PubMed publication ID

28 August 2017

https://scigraph.springernature.com/pub.10.1007/s00280-013-2121-1

0 references

Targeting the MAPK-RAS-RAF signaling pathway in cancer therapy

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2121-1

21 January 2018

Targeting the phosphoinositide 3-kinase pathway in cancer

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2121-1

21 January 2018

Therapeutic resistance resulting from mutations in Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR signaling pathways.

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2121-1

21 January 2018

The PI3K pathway as drug target in human cancer

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2121-1

21 January 2018

The emerging mechanisms of isoform-specific PI3K signalling

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2121-1

21 January 2018

Roles of the Raf/MEK/ERK pathway in cell growth, malignant transformation and drug resistance

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2121-1

21 January 2018

The Ras-ERK and PI3K-mTOR pathways: cross-talk and compensation

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2121-1

21 January 2018

Phosphatidylinositol-3-OH kinase as a direct target of Ras

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2121-1

21 January 2018

Identification of S664 TSC2 phosphorylation as a marker for extracellular signal-regulated kinase mediated mTOR activation in tuberous sclerosis and human cancer

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2121-1

21 January 2018

Phosphorylation and regulation of Raf by Akt (protein kinase B)

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2121-1

21 January 2018

Cross-talk between mitogenic Ras/MAPK and survival PI3K/Akt pathways: a fine balance.

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2121-1

21 January 2018

Targeting phosphatidylinositol 3 kinase (PI3K)-Akt beyond rapalogs

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2121-1

21 January 2018

Phase I, dose-escalation study of BKM120, an oral pan-Class I PI3K inhibitor, in patients with advanced solid tumors

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2121-1

21 January 2018

Targeting RAS signalling pathways in cancer therapy

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2121-1

21 January 2018

Improved survival with vemurafenib in melanoma with BRAF V600E mutation

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2121-1

21 January 2018

Improved survival with MEK inhibition in BRAF-mutated melanoma

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2121-1

21 January 2018

Clinical experience of MEK inhibitors in cancer therapy

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2121-1

21 January 2018

Multi-institutional phase II study of selumetinib in patients with metastatic biliary cancers

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2121-1

21 January 2018

Multicenter phase II study of the oral MEK inhibitor, CI-1040, in patients with advanced non-small-cell lung, breast, colon, and pancreatic cancer

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2121-1

21 January 2018

A phase II open-label randomized study to assess the efficacy and safety of selumetinib (AZD6244 [ARRY-142886]) versus capecitabine in patients with advanced or metastatic pancreatic cancer who have failed first-line gemcitabine therapy.

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2121-1

21 January 2018

PI3K inhibition results in enhanced HER signaling and acquired ERK dependency in HER2-overexpressing breast cancer

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2121-1

21 January 2018

Genetic predictors of MEK dependence in non-small cell lung cancer

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2121-1

21 January 2018

MEK inhibition leads to PI3K/AKT activation by relieving a negative feedback on ERBB receptors

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2121-1

21 January 2018

Differences underlying EGFR and HER2 oncogene addiction

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2121-1

21 January 2018

Ras in cancer and developmental diseases

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2121-1

21 January 2018

Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2121-1

21 January 2018

Identification and characterization of NVP-BKM120, an orally available pan-class I PI3-kinase inhibitor

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2121-1

21 January 2018

K-RAS mutant pancreatic tumors show higher sensitivity to MEK than to PI3K inhibition in vivo

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2121-1

21 January 2018

Mutations in the phosphatidylinositol-3-kinase pathway predict for antitumor activity of the inhibitor PX-866 whereas oncogenic Ras is a dominant predictor for resistance

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2121-1

21 January 2018

Comprehensive predictive biomarker analysis for MEK inhibitor GSK1120212.

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2121-1

21 January 2018

PI3K pathway activation mediates resistance to MEK inhibitors in KRAS mutant cancers

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2121-1

21 January 2018

KRAS mutant lung cancer cells are differentially responsive to MEK inhibitor due to AKT or STAT3 activation: implication for combinatorial approach

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2121-1

21 January 2018

Transcriptional pathway signatures predict MEK addiction and response to selumetinib (AZD6244)

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2121-1

21 January 2018

Inhibition of Mutated, Activated BRAF in Metastatic Melanoma

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2121-1

21 January 2018

Mutations of the BRAF gene in human cancer

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2121-1

21 January 2018

Potential therapeutic strategies to overcome acquired resistance to BRAF or MEK inhibitors in BRAF mutant cancers

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2121-1

21 January 2018

BRAF gene amplification can promote acquired resistance to MEK inhibitors in cancer cells harboring the BRAF V600E mutation

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2121-1

21 January 2018

RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E)

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2121-1

21 January 2018

Elevated CRAF as a potential mechanism of acquired resistance to BRAF inhibition in melanoma

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2121-1

21 January 2018

COT drives resistance to RAF inhibition through MAP kinase pathway reactivation

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2121-1

21 January 2018

Acquired resistance to BRAF inhibition can confer cross-resistance to combined BRAF/MEK inhibition.

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2121-1

21 January 2018

Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2121-1

21 January 2018

Dissecting therapeutic resistance to RAF inhibition in melanoma by tumor genomic profiling

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2121-1

21 January 2018

Activity of the oral MEK inhibitor trametinib in patients with advanced melanoma: a phase 1 dose-escalation trial

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2121-1

21 January 2018

Combinations of BRAF, MEK, and PI3K/mTOR inhibitors overcome acquired resistance to the BRAF inhibitor GSK2118436 dabrafenib, mediated by NRAS or MEK mutations

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2121-1

21 January 2018

RAS mutations are associated with the development of cutaneous squamous cell tumors in patients treated with RAF inhibitors

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2121-1

21 January 2018

RAS mutations in cutaneous squamous-cell carcinomas in patients treated with BRAF inhibitors

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2121-1

21 January 2018

Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2121-1

21 January 2018

Reversing melanoma cross-resistance to BRAF and MEK inhibitors by co-targeting the AKT/mTOR pathway.

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2121-1

21 January 2018

Combinatorial treatments that overcome PDGFRβ-driven resistance of melanoma cells to V600EB-RAF inhibition

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2121-1

21 January 2018

Acquired resistance to BRAF inhibitors mediated by a RAF kinase switch in melanoma can be overcome by cotargeting MEK and IGF-1R/PI3K

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2121-1

21 January 2018

Clinical Correlates of NRAS and BRAF Mutations in Primary Human Melanoma

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2121-1

21 January 2018

BRAF mutation predicts sensitivity to MEK inhibition

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2121-1

21 January 2018

Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2121-1

21 January 2018

Phase II, open-label, randomized trial of the MEK1/2 inhibitor selumetinib as monotherapy versus temozolomide in patients with advanced melanoma

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2121-1

21 January 2018

Combined PI3K/mTOR and MEK inhibition provides broad antitumor activity in faithful murine cancer models

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2121-1

21 January 2018

American Society of Clinical Oncology provisional clinical opinion: testing for KRAS gene mutations in patients with metastatic colorectal carcinoma to predict response to anti-epidermal growth factor receptor monoclonal antibody therapy

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2121-1

21 January 2018

KRAS, BRAF, PIK3CA, and PTEN mutations: implications for targeted therapies in metastatic colorectal cancer.

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2121-1

21 January 2018

Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2121-1

21 January 2018

Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2121-1

21 January 2018

Addition of cetuximab to chemotherapy as first-line treatment for KRAS wild-type metastatic colorectal cancer: pooled analysis of the CRYSTAL and OPUS randomised clinical trials

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2121-1

21 January 2018

A role for K-ras in conferring resistance to the MEK inhibitor, CI-1040.

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2121-1

21 January 2018

Identification of predictive markers of response to the MEK1/2 inhibitor selumetinib (AZD6244) in K-ras-mutated colorectal cancer.

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2121-1

21 January 2018

PIK3CA mutation uncouples tumor growth and cyclin D1 regulation from MEK/ERK and mutant KRAS signaling

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2121-1

21 January 2018

Intrinsic resistance to the MEK1/2 inhibitor AZD6244 (ARRY-142886) is associated with weak ERK1/2 signalling and/or strong PI3K signalling in colorectal cancer cell lines

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2121-1

21 January 2018

PIK3CA mutation in colorectal cancer: relationship with genetic and epigenetic alterations.

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2121-1

21 January 2018

The synergistic interaction of MEK and PI3K inhibitors is modulated by mTOR inhibition

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2121-1

21 January 2018

Inhibition of MEK and PI3K/mTOR suppresses tumor growth but does not cause tumor regression in patient-derived xenografts of RAS-mutant colorectal carcinomas

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2121-1

21 January 2018

Rethinking ovarian cancer: recommendations for improving outcomes

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2121-1

21 January 2018

Molecular pathogenesis and extraovarian origin of epithelial ovarian cancer--shifting the paradigm

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2121-1

21 January 2018

Ovarian tumorigenesis: a proposed model based on morphological and molecular genetic analysis

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2121-1

21 January 2018

In vivo activity of combined PI3K/mTOR and MEK inhibition in a Kras(G12D);Pten deletion mouse model of ovarian cancer

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2121-1

21 January 2018

Impact of KRAS mutations on clinical outcomes in pancreatic cancer patients treated with first-line gemcitabine-based chemotherapy

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2121-1

21 January 2018

Oncogenic Kras is required for both the initiation and maintenance of pancreatic cancer in mice

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2121-1

21 January 2018

Inhibition of PI3K/AKT and MAPK/ERK pathways causes activation of FOXO transcription factor, leading to cell cycle arrest and apoptosis in pancreatic cancer

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2121-1

21 January 2018

Phase I and pharmacodynamic study of the oral MEK inhibitor CI-1040 in patients with advanced malignancies

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2121-1

21 January 2018

Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2121-1

21 January 2018

Triple negative breast cancer: unmet medical needs

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2121-1

21 January 2018

Rare oncogenic mutations of predictive markers for targeted therapy in triple-negative breast cancer

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2121-1

21 January 2018

In vivo antitumor activity of MEK and phosphatidylinositol 3-kinase inhibitors in basal-like breast cancer models.

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2121-1

21 January 2018

Basal subtype and MAPK/ERK kinase (MEK)-phosphoinositide 3-kinase feedback signaling determine susceptibility of breast cancer cells to MEK inhibition

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2121-1

21 January 2018

Safety, pharmacokinetic, pharmacodynamic, and efficacy data for the oral MEK inhibitor trametinib: a phase 1 dose-escalation trial

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2121-1

21 January 2018

Ocular toxicity of targeted therapies

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2121-1

21 January 2018

Molecular profiling of patients with colorectal cancer and matched targeted therapy in phase I clinical trials.

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2121-1

21 January 2018

Identifiers

10.1007/S00280-013-2121-1

1 reference

Europe PubMed Central

PubMed publication ID

28 August 2017

Dimensions Publication ID

0 references

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

28 August 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q38084846&oldid=1421310905"